<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Corticosteroids for tuberculous pleurisy - Ryan, H - 2017 | Cochrane Library</title> <meta content="Corticosteroids for tuberculous pleurisy - Ryan, H - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001876.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Corticosteroids for tuberculous pleurisy - Ryan, H - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001876.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001876.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Corticosteroids for tuberculous pleurisy" name="citation_title"/> <meta content="Hannah Ryan" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Hannah.Ryan@lstmed.ac.uk" name="citation_author_email"/> <meta content="Jinho Yoo" name="citation_author"/> <meta content="Kyung Hee University" name="citation_author_institution"/> <meta content="Padmapriya Darsini" name="citation_author"/> <meta content="The National Institute for Reseach in Tuberculosis" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD001876.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/03/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001876.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001876.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001876.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects, *therapeutic use]; Antitubercular Agents [therapeutic use]; HIV Seronegativity; HIV Seropositivity [mortality]; Pleura [drug effects]; Randomized Controlled Trials as Topic; Tuberculosis, Pleural [*drug therapy, mortality]; Tuberculosis, Pulmonary [drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001876.pub3&amp;doi=10.1002/14651858.CD001876.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001876\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001876\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD001876.pub3",title:"Corticosteroids for tuberculous pleurisy",firstPublishedDate:"Mar 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001876.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001876.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001876.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001876.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001876.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001876.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001876.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001876.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001876.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001876.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7588 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001876.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0023"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0024"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0029"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0030"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/appendices#CD001876-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/table_n/CD001876StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/table_n/CD001876StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Corticosteroids for tuberculous pleurisy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#CD001876-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hannah Ryan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#CD001876-cr-0003">Jinho Yoo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information#CD001876-cr-0004">Padmapriya Darsini</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information/en#CD001876-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 March 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001876.pub3">https://doi.org/10.1002/14651858.CD001876.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001876-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001876-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001876-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001876-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001876-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001876-abs-0001" lang="en"> <section id="CD001876-sec-0001"> <h3 class="title" id="CD001876-sec-0001">Background</h3> <p>Corticosteroids used in addition to antituberculous therapy have been reported to benefit people with tuberculous pleurisy. However, research findings are inconsistent and raise doubt as to whether such treatment is worthwhile. There is also concern regarding the potential adverse effects of corticosteroids, especially in HIV‐positive people. </p> </section> <section id="CD001876-sec-0002"> <h3 class="title" id="CD001876-sec-0002">Objectives</h3> <p>To evaluate the effects of adding corticosteroids to drug regimens for tuberculous pleural effusion. </p> </section> <section id="CD001876-sec-0003"> <h3 class="title" id="CD001876-sec-0003">Search methods</h3> <p>In April 2016, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (the Cochrane Library), MEDLINE, Embase, LILACS, Current Controlled Trials, and the reference lists of articles identified by the literature search. </p> </section> <section id="CD001876-sec-0004"> <h3 class="title" id="CD001876-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) and quasi‐RCTs that compared any corticosteroid with no treatment, placebo, or other active treatment (both groups should have received the same antituberculous drug regimen) in people diagnosed with tuberculous pleurisy. </p> </section> <section id="CD001876-sec-0005"> <h3 class="title" id="CD001876-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened the search results, extracted data from the included trials, and assessed trial methodological quality using the Cochrane 'Risk of bias' tool. We analysed the data using risk ratios (RR) with 95% confidence intervals (CIs). We applied the fixed‐effect model in the absence of statistically significant heterogeneity. </p> </section> <section id="CD001876-sec-0006"> <h3 class="title" id="CD001876-sec-0006">Main results</h3> <p>Six trials with 590 participants met the inclusion criteria, which were conducted in Asia (three trials), Africa (two trials), and Europe (one trial). Two trials were in HIV‐negative people, one trial was in HIV‐positive people, and three trials did not report HIV status. </p> <p>Corticosteroids may reduce the time to resolution of pleural effusion. Risk of residual pleural effusion on chest X‐ray was reduced by 45% at eight weeks (RR 0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials, <i>low certainty evidence</i> ), and 65% at 24 weeks (RR 0.35, 95% CI 0.18 to 0.66; 237 participants, 2 trials, <i>low certainty evidence</i>). </p> <p>Compared with control, corticosteroids may reduce the risk of having pleural changes (such as pleural thickening or pleural adhesions), on chest X‐ray at the end of follow‐up by almost one third (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials,<i>low certainty evidence</i>), which translates to an absolute risk reduction of 16%. </p> <p>One trial reported deaths in people that were HIV‐positive, with no obvious difference between the groups; the trial authors' analysis suggests that the deaths observed in this trial were related to HIV disease rather than pleural TB (RR 0.91, 95% CI 0.64 to 1.31; 197 participants, 1 trial). </p> <p>We found limited data on long‐term functional respiratory impairment on 187 people in two trials, which reported that average percentage predicted forced vital capacity was similar in the group receiving prednisolone and in the control group (<i>very low certainty evidence</i>). </p> <p>The risk of adverse events that led to discontinuation of the trial drug was higher in people with pleural TB receiving corticosteroids (RR 2.78, 95% CI 1.11 to 6.94; 587 participants, 6 trials, <i>low certainty evidence</i> ). The trial in HIV‐positive people reported on six different HIV‐related infections, with no obvious differences. However, cases of Kaposi's sarcoma were only seen in the corticosteroid group (with 6/99 cases in the steroid group compared to 0/98 in the control group) (<i>very low certainty evidence</i>). </p> </section> <section id="CD001876-sec-0007"> <h3 class="title" id="CD001876-sec-0007">Authors' conclusions</h3> <p>Long‐term respiratory function is potentially the most important outcome for assessing the effects of adjunctive treatments for people with pleural TB. However, the information on the impact of pleural TB on long‐term respiratory function is unknown and could be eclipsed by other risk factors, such as concurrent pulmonary TB, smoking, and HIV. This probably needs to be quantified to help decide whether further trials of corticosteroids for pleural TB would be worthwhile. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001876-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001876-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001876-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001876-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001876-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001876-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001876-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001876-abs-0003" lang="en"> <h3>What is tuberculous pleurisy and how might corticosteroids work?</h3> <p>Tuberculous pleurisy results from inflammation of the membrane that covers the lungs (the pleura) caused by exposure to <i>Mycobacterium tuberculosis</i> bacteria infecting the lungs. This results in a build up of fluid around the lung (pleural effusion) that causes pain and fever, impairs breathing, and may lead to impairment of lung function in the long term. </p> <p>Some clinicians believe that corticosteroids used in combination with antituberculous drugs can speed up the recovery from TB pleurisy and help to prevent long‐term complications. </p> <p><b>What the evidence shows</b> </p> <p>We examined the available evidence up to 13 April 2016 and included six trials with 590 people, which evaluated prednisolone given with antituberculous treatment (ATT). One included trial was of high quality, while the rest had uncertainties regarding trial quality. All the included trials were in adults; one trial included only HIV‐positive people, two included only HIV‐negative people, and three did not report the HIV status of the participants. </p> <p>Corticosteroids may reduce the time to resolution of the symptoms of TB pleurisy and the time to resolution of the pleural effusion on chest X‐ray (<i>low certainty evidence).</i> Corticosteroids may also reduce the risk of having signs of pleural scarring on chest X‐ray (pleural thickening and pleural adhesions) after the disease has resolved (<i>low certainty evidence</i> ). There was not enough information about lung function to be sure whether or not corticosteroids reduce the risk of lung function impairment after TB pleurisy (<i>very low certainty evidence</i>). </p> <p>Corticosteroids may increase the risk of adverse events leading to discontinuation of the trial drug (<i>low certainty evidence</i> ). From one trial in people living with HIV, there was no detectable increase in HIV‐related conditions with corticosteroids, although cases of Kaposi's sarcoma were only seen in the corticosteroid group and numbers of participants and events were too small to rule out an effect of corticosteroids (<i>very low certainty evidence</i>). </p> <p>As the risk of disability and long‐term illness after TB pleurisy is unclear, research looking at the association between TB pleurisy and lung function impairment would be useful to inform future research into corticosteroids for TB pleurisy. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001876-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001876-sec-0087"></div> <h3 class="title" id="CD001876-sec-0088">Implications for practice</h3> <section id="CD001876-sec-0088"> <p>The included trials in this review do not provide substantive evidence on patient‐important outcomes to guide recommendations on the use of corticosteroids in people with TB pleurisy. The efficacy of corticosteroids in reducing the time to resolution of pleural effusion or symptoms is uncertain, although the included trials that were at low risk of bias did demonstrate more rapid resolution of pleural effusion on chest X‐ray in participants treated with corticosteroids. There may be a decreased risk of pleural changes such as pleural thickening and pleural adhesions on chest X‐ray at the end of treatment with corticosteroids, but it is unclear how this relates to patient‐important outcomes such as disability, lung function, and mortality. The concerns raised regarding adverse events in both HIV‐negative and HIV‐positive people with pleural TB need to be taken into account when deciding whether or not to use corticosteroids. </p> <p>Current guidelines for TB treatment do not recommend the use of corticosteroids in pleural TB (<a href="./references#CD001876-bbs2-0049" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extrapulmonary Tuberculosis for India. New Delhi: Ministry of Health and Family Welfare, Government of India, 2016. ">INDEX‐TB 2016</a>; <a href="./references#CD001876-bbs2-0058" title="National Institute for Health and Care Excellence. NICE Guideline NG33: Tuberculosis. National Institute for Health and Care Excellence, May 2016. ">NICE 2016</a>; <a href="./references#CD001876-bbs2-0069" title="World Health Organization. Treatment of Tuberculosis Guidelines. 4th Edition. Geneva: World Health Organization, 2010. ">WHO 2010</a>). </p> </section> <h3 class="title" id="CD001876-sec-0089">Implications for research</h3> <section id="CD001876-sec-0089"> <p>The literature search performed for this update revealed no new trials that compared corticosteroids to placebo in people with pleural TB, and no trials are ongoing at the time of publication of this Cochrane Review. We prepared a rapid update of this review as part of the development process of guidelines on extrapulmonary TB in India, the INDEX‐TB Guidelines (<a href="./references#CD001876-bbs2-0049" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extrapulmonary Tuberculosis for India. New Delhi: Ministry of Health and Family Welfare, Government of India, 2016. ">INDEX‐TB 2016</a>). During discussions regarding the use of corticosteroids for pleural TB, the guideline panel noted that, as pleural TB is generally associated with low mortality, the priority outcome for consideration is lung function. The panel felt that the main outcomes in the available studies are at best proxy measures for lung function, and, given the evidence for adverse effects of corticosteroids, made a conditional recommendation against their use in pleural TB. </p> <p>It is notable that the two trials included in this review that do report on lung function suggest that, while there was no qualitative difference between the two treatment groups, many people who have been successfully treated for pleural TB have poorer than expected lung function. There are still questions to be answered regarding lung function, disability, and mortality after pleural TB. </p> <p>A systematic review of studies that investigated the prevalence of chronic lung disease in general populations concluded that pulmonary TB is strongly associated with chronic lung disease, including chronic obstructive pulmonary disease (COPD) and bronchiectasis (<a href="./references#CD001876-bbs2-0036" title="ByrneAL , MaraisBJ , MitnickCD , LeccaL , MarksGB . Tuberculosis and chronic respiratory disease: a systematic review. International Journal of Infectious Diseases2015;32:138‐46. ">Byrne 2015</a>). Two studies included in the review showed a stronger association between pulmonary TB and chronic lung disease in non‐smokers than in smokers, which suggested that the relationship is not due to confounding risk factors alone. Indeed, the association between pulmonary TB and chronic lung disease has been recognized for many decades. More recently the interconnected causal relationships between TB, HIV, smoking, and chronic lung disease have been further elucidated, although many questions regarding pathophysiology remain unanswered (<a href="./references#CD001876-bbs2-0068" title="vanZyl SmitRN , PaiM , YewWW , LeungCC , ZumlaA , BatemanED , et al. Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD. European Respiratory Journal2010;35(1):27‐33. ">van Zyl Smit 2010</a>). There is less evidence regarding the association between pleural TB and chronic lung disease or respiratory impairment. <a href="./references#CD001876-bbs2-0037" title="CandelaA , AndujarJ , HernándezL , MartínC , BarrosoE , ArrieroJM , et al. Functional sequelae of tuberculous pleurisy in patients correctly treated. Chest2003;123(6):1996‐2000. ">Candela 2003</a> reported on functional sequelae in terms of pulmonary function testing in a cohort of 81 Spanish adults with pleural TB with a median follow‐up time of 23 months after diagnosis. Investigators found that 8/81 (10%) of the participants had a restrictive ventilatory deficit (one or both of FVC and TLC &lt; 80% of predicted, with a FEV<sub>1</sub>/FVC ratio &gt; 80% of predicted) at the end of follow‐up, which they describe as mild to moderate in all but two cases who were both smokers with a pre‐existing diagnosis of COPD. They found no statistically significant association between residual pleural thickening on chest X‐ray and functional sequelae at end of follow‐up, although the sample was too small to rule out an association. They also found that the pleural fluid profile of participants that went on to have a restrictive ventilatory deficit demonstrated lower levels of lactate dehydrogenase and higher lymphocyte count, suggesting a difference in the inflammatory response in the pleural space. Their results provide context to the results of this review: if there is poor correlation between pleural thickening on chest X‐ray and functional sequelae, we cannot conclude that if corticosteroids reduce pleural thickening they are likely to be of benefit in terms reducing rates of lung function impairment. </p> <p>Given the uncertainties that exist, further research is warranted to explore the relevance of discriminating between people presenting with isolated pleural TB and pleuro‐pulmonary TB, using different imaging modalities such as computed tomography and ultrasound. Cohort studies are needed in people who have pleural TB of either type to assess the incidence of functional sequelae, as measured using spirometry and also disability metrics validated for disability related to impaired lung function. The utility of further randomized controlled trials for corticosteroids in pleural TB would be informed by the results of such research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001876-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001876-sec-0023"></div> <div class="table" id="CD001876-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Steroids compared with placebo for pleural TB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and adolescents with pleural TB </p> <p><b>Settings:</b> hospital care and community follow‐up </p> <p><b>Intervention:</b> corticosteroids </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks¹ (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual pleural fluid on chest X‐ray at 8 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> </p> <p>(23 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.54 </p> <p>(0.37 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2,3,4</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual pleural fluid on chest X‐ray at 24 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> <p>(5 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.35 </p> <p>(0.18 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2,3,4</sup> </p> <p><b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pleural changes at the end of follow‐up</b> </p> <p>(pleural adhesions or pleural thickening on chest X‐ray; follow‐up 6 to 24 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> </p> <p>(29 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.72 </p> <p>(0.57 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393</p> <p>(5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>5,6,7</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term functional respiratory impairment (&gt; 6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average percentage predicted FVC similar in corticosteroid and control groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> </p> <p>(follow‐up 6 to 24 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 2.78 </p> <p>(1.11 to 6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590<br/> (6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>9,10</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV‐related infections (cryptococcal meningitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> <p>(1 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.59 </p> <p>(0.15 to 2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>11,12</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV‐related cancer (Kaposi's sarcoma)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><sup>13</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> <p>(1 to 316)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 12.87 </p> <p>(0.73 to 225.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>14,15</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>¹The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; RR: risk ratio; TB: tuberculosis; FVC: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one for risk of bias: of the four trials that reported this outcome, we excluded two trials from the final analysis due to high risk of selection bias, after a subgroup analysis suggested the pooled estimate including these studies could be misleading (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). We judged this to be our best estimate of effect. However because we excluded trials from this analysis this generates uncertainty, so we have downgraded the quality of the evidence.<br/> <sup>2</sup>Not downgraded for inconsistency: heterogeneity in the original meta‐analysis was likely due to differences in study quality. A subgroup analysis showed that statistical heterogeneity disappeared when we excluded trials that were at high risk of selection bias.<br/> <sup>3</sup>Downgraded by one for imprecision: the CI around the summary effect estimate is wide due to the small number of participants and events in each included trial.<br/> <sup>4</sup>Not downgraded for indirectness: the included trials were performed in different settings and time periods and used widely available drugs and diagnostic techniques. Although the trials did not include children, we did not downgrade as pleural TB is less common in children than in adults. One trial included HIV‐positive people, <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>, and this trial contributed most of the participants in the meta‐analysis. When making recommendations relating to the use of corticosteroids for pleural TB in children or in HIV‐negative adults, guideline panels may wish to consider downgrading for indirectness.<br/> <sup>5</sup>Downgraded by one for serious risk of bias: we assessed two trials as at high risk of bias for randomization method (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>), and the other three trials were at unclear risk of bias (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). Only <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> reported that outcome assessors were blinded to the treatment allocation.<br/> <sup>6</sup>Downgraded by one for serious imprecision: the CI around the summary effect estimate is wide, ranging from a maximum risk reduction with steroids of 43% to a minimum risk reduction of 7%, which may not be clinically significant when weighed against possible harms of steroids.<br/> <sup>7</sup>Not downgraded for indirectness: the trials were performed in a variety of settings, and all used drugs and diagnostic techniques that are widely available. We did not include any HIV‐positive people in this meta‐analysis, so when making recommendations regarding the use of corticosteroids in HIV‐positive people with TB pleurisy, guideline panels may wish to consider downgrading for indirectness. Only one trial included children aged over 11 years of age (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>), but we did not downgrade as pleural TB is not common in children.<br/> <sup>8</sup>Two of the six trials reported pulmonary function tests at the end of treatment (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), but data were insufficient to combine these outcomes in a meta‐analysis. The data are in <a href="#CD001876-tbl-0008">Table 7</a>, and suggest that in these trials there was little or no difference in mean percentage predicted FVC at the end of treatment. The number of participants in each group with pulmonary function tests suggestive of a functional respiratory impairment are not reported.<br/> <sup>9</sup>Downgraded by one for risk of bias: there were concerns about randomization method and allocation concealment. Additionally, reporting of adverse events varied significantly across the trials, and some trials only reported on adverse events in the steroid group, and it is likely that some trials did not detect or report all adverse events.<br/> <sup>10</sup>Downgraded by one for serious imprecision: the CI around the summary effect estimate is wide, with a maximum increased risk of adverse effects leading to study drug discontinuation of nearly 700% and a minimum increased risk of 12%, which may not be clinically significant when weighed against possible benefits of steroids.<br/> <sup>11</sup>Downgraded by two for serious imprecision: the CI around the summary effect estimate is very wide, and possible effects range from large benefits to significant harms.<br/> <sup>12</sup>Downgraded by one for indirectness: only one trial included HIV‐positive people and assessed HIV‐related adverse events (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). Participants in this trial were not treated with antiretroviral therapy, which is known to prevent cryptococcal meningitis in HIV‐positive people; therefore this estimate may not be applicable to HIV‐positive people on antiretroviral therapy. This trial did not include any children.<br/> <sup>13</sup>Prevalence of Kaposi's sarcoma of 1.4% in HIV‐positive adults on clinic enrolment taken from <a href="./references#CD001876-bbs2-0063" title="SemeereA , WengerM , BusakhalaN , BuzibaN , BwanaM , MuyindikeW , et al. A prospective ascertainment of cancer incidence in sub‐Saharan Africa: the case of Kaposi sarcoma. Cancer Medicine2016;5(5):914‐28. ">Semeere 2016</a>, a multi‐centre prospective cohort study performed in Uganda and Kenya.<br/> <sup>14</sup>Downgraded by two for serious imprecision: the CI around the summary effect estimate is very wide, and possible effects range from large benefits to significant harms.<br/> <sup>15</sup>Downgraded by one for indirectness: only one trial included HIV‐positive people and assessed HIV‐related adverse events (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). Participants in this trial were not treated with antiretroviral therapy, which is known to treat and prevent Kaposi's sarcoma in HIV‐positive people, therefore this estimate may not be applicable to HIV‐positive people on antiretroviral therapy. This trial did not include any children. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001876-sec-0024" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001876-sec-0024"></div> <p>Tuberculosis (TB) is an infectious disease caused by <i>Mycobacterium tuberculosis</i> complex, and is a major cause of illness and death worldwide. In 2014 approximately 9.6 million people newly developed the disease and there were 1.5 million deaths globally (<a href="./references#CD001876-bbs2-0070" title="World Health Organization. Global Tuberculosis Report 2015. Global Tuberculosis Report 2015. Geneva: World Health Organization, 2015. ">WHO 2015</a>). TB infects the lungs, and is transmitted by droplet spread from coughing people with active pulmonary TB, but it can also spread to other body sites and cause extrapulmonary TB (EPTB). </p> <section id="CD001876-sec-0025"> <h3 class="title" id="CD001876-sec-0025">Description of the condition</h3> <p>Pleural TB is one of the most common forms of EPTB, with an incidence of 3% to 25% of people with TB (<a href="./references#CD001876-bbs2-0056" title="LightRW . Update on tuberculous pleural effusion. Respirology2010;15(3):451–8. ">Light 2010</a>; <a href="./references#CD001876-bbs2-0064" title="SharmaSK , MohanA . Extrapulmonary tuberculosis. Indian Journal of Medical Research2004;120(4):316‐53. ">Sharma 2004</a>). The incidence is higher in high TB prevalence settings (<a href="./references#CD001876-bbs2-0050" title="JeonD . Tuberculous pleurisy: an update. Tuberculosis and Respiratory Diseases2014;76(4):153‐9. ">Jeon 2014</a>). Immune compromise is an important risk factor for all forms of TB, and evidence suggests that pleural TB is more common in people living with HIV (<a href="./references#CD001876-bbs2-0033" title="BatungwanayoJ , TaelmanH , AllenS , BogaertsJ , KagameA , Van dePerreP . Pleural effusion, tuberculosis and HIV‐1 infection in Kigali, Rwanda. AIDS1993;7(1):73‐9. ">Batungwanayo 1993</a>; <a href="./references#CD001876-bbs2-0046" title="FryeMD , PozsikCJ , SahnSA . Tuberculous pleurisy is more common in AIDS than in non‐AIDS patients with tuberculosis. Chest1997;112(2):393‐7. ">Frye 1997</a>; <a href="./references#CD001876-bbs2-0059" title="PozniakAL , MacLeodGA , NdlovuD , RossE , MahariM , WeinbergJ . Clinical and chest radiographic features of tuberculosis associated with human immunodeficiency virus in Zimbabwe. American Journal of Respiratory and Critical Care Medicine1995;152(5 Pt 1):1558–61. ">Pozniak 1995</a>; <a href="./references#CD001876-bbs2-0062" title="SaksAM , PosnerR . Tuberculosis in HIV positive patients in SouthAfrica: a comparative radiological study with HIV negative patients. Clinical Radiology1992;46(6):387‐90. ">Saks 1992</a>). Pleural TB can be a manifestation of TB disease post‐primary infection, or due to reactivation of latent TB (<a href="./references#CD001876-bbs2-0056" title="LightRW . Update on tuberculous pleural effusion. Respirology2010;15(3):451–8. ">Light 2010</a>). </p> <p>Clinically, pleural TB presents as an acute illness consisting of cough, fever, chest pain, and shortness of breath (<a href="./references#CD001876-bbs2-0057" title="MoreheadRS . Tuberculosis of the pleura. Southern Medical Journal1998;91(7):630‐6. ">Morehead 1998</a>), and usually a pleural effusion is demonstrated on chest X‐ray. Pleural TB usually resolves without treatment of any kind, but untreated patients may experience longer duration of the acute symptoms and risk recurrence of active TB at a later point in time (<a href="./references#CD001876-bbs2-0056" title="LightRW . Update on tuberculous pleural effusion. Respirology2010;15(3):451–8. ">Light 2010</a>). Pleural TB can be complicated by massive effusion leading to respiratory compromise in the short term, and pleural thickening, fibrosis, and pleural adhesions causing impaired respiratory function in the medium‐ to long‐term. </p> <p>Pleural TB is thought to be caused by a delayed type (type IV) hypersensitivity reaction following release of mycobacterial antigens into the pleural space (<a href="./references#CD001876-bbs2-0061" title="RossiGA , BalbiB , MancaF . Tuberculous pleural effusions. Evidence for selective presence of PPD‐specific T‐lymphocytes at site of inflammation in the early phase of the infection. American Review of Respiratory Disease1987;136(3):575‐9. ">Rossi 1987</a>), as a result of rupture of a subpleural focus of TB infection in the lung (<a href="./references#CD001876-bbs2-0066" title="SteadWW , EichenholzA , StaussH‐K . Operative and pathologic findings in twenty‐four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous. American Review of Tuberculosis1955;71(4):473–502. ">Stead 1955</a>). This explains the tendency towards resolution of the effusion and associated symptoms with or without treatment of the TB infection, and the fact that culture of pleural fluid is nearly always negative for <i>M. tuberculosis</i>. There appears to be a spectrum of disease in pleural TB in terms of the extent of the underlying lung infection, which could be important in terms of patient outcomes and the potential for corticosteroids to be effective (<a href="#CD001876-tbl-0002">Table 1</a>). A systematic review that includes 18 trials and 3816 participants suggests that corticosteroids probably do not improve mortality rates, sputum smear or culture conversion in people with pulmonary TB (<a href="./references#CD001876-bbs2-0040" title="CritchleyJA , OrtonLC , PearsonF . Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database of Systematic Reviews2014, Issue 11. [DOI: 10.1002/14651858.CD011370] ">Critchley 2014</a>). One cohort study of people with pleural TB in Spain reported evidence of pulmonary TB infection on chest X‐ray in 20% of 254 participants (<a href="./references#CD001876-bbs2-0067" title="ValdésL , AlvarezD , San JoséE , PenelaP , ValleJM , García‐PazosJM , et al. Tuberculous pleurisy: a study of 254 patients. Archives of Internal Medicine1998;158(18):2017‐21. ">Valdés 1998</a>). Pulmonary involvement rose to 86% in another cohort where computed tomography (CT) scanning was used (<a href="./references#CD001876-bbs2-0053" title="KimHJ , LeeHJ , KwonSY , YoonHI , ChungHS , LeeCT , et al. The prevalence of pulmonary parenchymal tuberculosis in patients with tuberculous pleuritis. Chest2006;129(5):1253‐8. ">Kim 2006</a>). <a href="./references#CD001876-bbs2-0065" title="ShuC‐C , WangJ‐T , WangJ‐Y , LeeL‐N , YuC‐J . In‐hospital outcome of patients with culture‐confirmed tuberculous pleurisy: clinical impact of pulmonary involvement. BMC Infectious Diseases2011;11:46. ">Shu 2011</a> demonstrated that pulmonary involvement (as defined by positive sputum culture and/or chest X‐ray appearances) was an important predictor of mortality in hospitalised pleural TB patients in Korea, and was associated with a longer hospital stay. </p> <div class="table" id="CD001876-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Theoretical framework describing differences between isolated tuberculous pleurisy and pulmonary TB with tuberculous pleurisy (pleuro‐pulmonary TB)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical Feature</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Isolated pleural TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pleuro‐pulmonary TB</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum microscopy/culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some positive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usually demonstrates exudative effusion</p> <p>Usually negative for <i>M. tuberculosis</i> on smear and culture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usually demonstrates exudative effusion</p> <p>Usually negative for <i>M. tuberculosis</i> on smear and culture </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest X‐ray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discrete pleural effusion, or pleural thickening, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural effusion with other changes such as consolidation, cavities, atelectasis, or hilar enlargement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest computed tomography (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May demonstrate underlying lung infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demonstrates underlying lung infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathogenesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predominantly driven by delayed type hypersensitivity reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predominantly driven by TB infection of the lung</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prognosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most people will improve with no antituberculous treatment (ATT), but may experience a relapse of TB infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People may deteriorate and die without ATT</p> </td> </tr> </tbody> </table> </div> <p>Diagnosis of pleural TB can be challenging with traditional microscopy and culture methods being relatively insensitive when used on pleural fluid, and newer modalities such as Xpert® MTB/RIF have similar limitations (<a href="./references#CD001876-bbs2-0041" title="DenkingerCM , SchumacherSG , BoehmeCC , DendukuriN , PaiM , SteingartKR . Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: asystematic review and meta‐analysis. European Respiratory Journal2014;44(2):435‐46. ">Denkinger 2014</a>). Histopathological examination and mycobacterial culture performed on pleural biopsy samples are regarded as more reliable tests, and yielded a diagnosis in 227/248 patients (91%) in one cohort study (<a href="./references#CD001876-bbs2-0067" title="ValdésL , AlvarezD , San JoséE , PenelaP , ValleJM , García‐PazosJM , et al. Tuberculous pleurisy: a study of 254 patients. Archives of Internal Medicine1998;158(18):2017‐21. ">Valdés 1998</a>). </p> </section> <section id="CD001876-sec-0026"> <h3 class="title" id="CD001876-sec-0026">Description of the intervention</h3> <p>Corticosteroids are hormones produced by the adrenal cortex which have a variety of physiological functions, including carbohydrate metabolism, protein catabolism, regulation of electrolytes, the stress response and control of inflammation. Corticosteroids induce their anti‐inflammatory effect through the regulation of gene expression in cells, leading to increased expression of genes which inhibit inflammatory pathways, and repression of genes encoding pro‐inflammatory proteins (<a href="./references#CD001876-bbs2-0032" title="BarnesPJ . How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology2006;148(3):245‐54. ">Barnes 2006</a>). Multiple synthetic forms of these hormones have been produced and are used in the treatment of a wide variety of inflammatory conditions. Prednisolone is a synthetic corticosteroid derived from cortisol, and prednisone is a pro‐drug that is converted into the active form prednisolone by the liver. Several formulations of each drug are used for different conditions and diseases; in TB pleurisy patients are usually offered them in tablet form. </p> <p>Corticosteroids have been used in medicine for many decades, and have well‐characterised adverse effect profiles. Adverse effects for medium to long‐term use include hyperglycaemia, hypertension, increased risk of infection, osteoporosis, gastric ulceration and gastrointestinal bleeding, thinning of the skin, proximal myopathy, psychiatric symptoms, and development of moon face, striae and acne (Cushing's syndrome). The use of synthetic corticosteroids can induce adrenocorticoid insufficiency, and so patients receiving more than one week's treatment must have the dose slowly reduced to avoid acute adrenal insufficiency causing hypotension and hypoglycaemia which can be life‐threatening (<a href="./references#CD001876-bbs2-0035" title="Joint Formulary Committee. British National Formulary. 72. London: BMJ Group and Pharmaceutical Press, 2016. ">BNF 2016</a>). </p> </section> <section id="CD001876-sec-0027"> <h3 class="title" id="CD001876-sec-0027">How the intervention might work</h3> <p>Therapeutic options for pleural space infections include intravenous antibiotic administration, chest tube drainage, intrapleural administration of a fibrinolytic agent to dissolve fibrous adhesions, thoracotomy to remove fibrinous and infected tissue, and steroid therapy (<a href="./references#CD001876-bbs2-0039" title="ChapmanSJ , DaviesRJ . The management of pleural space infections. Respirology2004;9(1):4‐11. ">Chapman 2004</a>). </p> <p>The theoretical basis for using corticosteroids is that they suppress the delayed type hypersensitivity inflammatory response triggered by the release of tubercular antigens into the pleural space which is believed to be responsible for tuberculous pleurisy. One corticosteroid is prednisone, which is converted in the liver into the active drug, prednisolone. Prednisolone is recommended at a daily dose of about 1 mg/kg gradually reducing after one to two weeks, with a total treatment course sometimes being as long as three months (<a href="./references#CD001876-bbs2-0055" title="LemaistreCA , TompsettR , MuschenheimC , MooreJA , McDermottW . Effects of adrenocorticotropic hormone and cortisone in patients with tuberculosis. Journal of Clinical Investigation1951;30(5):445‐56. ">Lemaistre 1951</a>; <a href="./references#CD001876-bbs2-0018" title="MathurKS , PrasadR , MathurJS . Intrapleural hydrocortisone in tuberculous pleural effusion. Tubercle1960;41:358‐62. ">Mathur 1960</a>; <a href="./references#CD001876-bbs2-0057" title="MoreheadRS . Tuberculosis of the pleura. Southern Medical Journal1998;91(7):630‐6. ">Morehead 1998</a>; <a href="./references#CD001876-bbs2-0034" title="BlumbergHM , BurmanWJ , ChaissonRE , DaleyCL , EtkindSC , FriedmanLN , et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine2003;167(4):603‐62. ">Blumberg 2003</a>). </p> <p>Corticosteroids have anti‐inflammatory properties, produced mainly via suppression of pro‐inflammatory gene expression and activation of anti‐inflammatory genes (<a href="./references#CD001876-bbs2-0032" title="BarnesPJ . How corticosteroids control inflammation: Quintiles Prize Lecture 2005. British Journal of Pharmacology2006;148(3):245‐54. ">Barnes 2006</a>). While the inflammatory response is necessary to control the infection, excessive inflammation can lead to tissue damage and fibrosis, which could cause long‐term morbidity. Suppression of the inflammatory response in pleural TB could reduce the symptoms and signs associated with the inflammatory process: fever, progression of the pleural effusion, malaise. Corticosteroids could therefore reduce the duration or severity of symptoms in the short term, and also reduce the risk of tissue damage leading to lung impairment in the long term. </p> </section> <section id="CD001876-sec-0028"> <h3 class="title" id="CD001876-sec-0028">Why it is important to do this review</h3> <p>Studies of adjunctive corticosteroids for the treatment of tuberculous pleural effusion show conflicting results. Non‐randomized studies in the pre‐HIV era found that corticosteroids led to more rapid resolution of the effusion and reduced likelihood of residual pleural thickening and pleural adhesions (<a href="./references#CD001876-bbs2-0021" title="MenonNK . Steroid therapy in tuberculous pleural effusion. Tubercle1964;45:17‐20. ">Menon 1964</a>; <a href="./references#CD001876-bbs2-0025" title="SinghD , YesikarSS . Role of intrapleural corticosteroids in tuberculous pleural effusion: a clinicotherapeutic trial of 50 cases. Journal of the Indian Medical Association1965;45(6):306‐9. ">Singh 1965</a>). An observational study of 165 HIV‐positive participants with tuberculous pleural effusion found that prednisolone was associated with decreasing rates of lymphadenopathy and cough as well as improved survival (<a href="./references#CD001876-bbs2-0043" title="ElliottAM , HalwiindiB , BagshaweA , HayesRJ , LuoN , PobeeJO , et al. Use of prednisolone in the treatment of HIV‐positive tuberculosis patients. Quarterly Journal of Medicine1992;85(307‐8):855‐60. ">Elliott 1992</a>; Elliott personal communication). </p> <p>In contrast, a critical appraisal of published studies demonstrated beneficial effects of corticosteroids on acute symptoms, but it found no benefit for chronic endpoints such as fibrosis, irrespective of dose (<a href="./references#CD001876-bbs2-0042" title="DooleyDP , CarpenterJL , RademacherS . Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clinical Infectious Diseases1997;25(4):872‐87. ">Dooley 1997</a>). The authors noted that many of the studies lacked rigour and clinical correlations. The previous version of this Cochrane review (<a href="./references#CD001876-bbs2-0071" title="EngelME , MatchabaPT , VolminkJ . Corticosteroids for tuberculous pleurisy. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD001876.pub2] ">Engel 2007</a>), which included six trials and 633 participants, concluded that data were insufficient to support the use of corticosteroids in pleural TB. </p> <p>In addition to the uncertainty about benefits of corticosteroid therapy, there is concern about potential risks. In immunocompromised patients, such as those infected with HIV, corticosteroids may further constrain the immune system leading to an increased frequency of opportunistic infections and tumours such as Kaposi's sarcoma, a vascular tumour accompanied by numerous unconnected lesions of the skin and associated with human herpes virus‐8 infection (<a href="./references#CD001876-bbs2-0044" title="EnsoliB , SgadariC , BarillariG , SirianniMC , StürzlM , MoniniP . Biology of Kaposi's sarcoma. European Journal of Cancer2001;37(10):1251‐69. ">Ensoli 2001</a>). More generally, adverse effects of corticosteroids such as fluid retention and gastrointestinal disturbances have also been documented in people with TB (<a href="./references#CD001876-bbs2-0031" title="Anonymous . Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum‐positive patients with pulmonary tuberculosis in South India. Tubercle1983;64(2):73‐91. ">Anonymous 1983</a>). Other adverse effects associated with corticosteroids include high blood pressure, high blood glucose or exacerbation of existing diabetes mellitus, weight gain, increased susceptibility to infection, gastrointestinal bleeding and in long‐term use osteoporosis and changes to the skin and face. </p> <p>We updated this review with the aim of adding any new evidence that may have been published since the previous search in 2007. For this version, we revised the protocol, and in particular altered the outcomes of interest. This was informed by discussions with expert clinicians which took place during the development of a new guideline on extrapulmonary TB in India, the INDEX‐TB guidelines (<a href="./references#CD001876-bbs2-0049" title="INDEX‐TB Guidelines Group. INDEX‐TB Guidelines ‐ Guidelines on Extrapulmonary Tuberculosis for India. New Delhi: Ministry of Health and Family Welfare, Government of India, 2016. ">INDEX‐TB 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001876-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001876-sec-0029"></div> <p>To evaluate the effects of adding corticosteroids to drug regimens for tuberculous pleural effusion. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001876-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001876-sec-0030"></div> <section id="CD001876-sec-0031"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001876-sec-0032"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) and quasi‐RCTs.</p> </section> <section id="CD001876-sec-0033"> <h4 class="title">Types of participants</h4> <p>People diagnosed with tuberculous pleurisy by chest x‐ray (as defined by trial authors) plus any of the following: pleural biopsy for histology; staining and microscopy for acid‐fast bacilli, or culture of sputum, or both; pleural fluid; or pleural biopsy. </p> </section> <section id="CD001876-sec-0034"> <h4 class="title">Types of interventions</h4> <section id="CD001876-sec-0035"> <h5 class="title">Intervention</h5> <p>Any corticosteroid at any dose.</p> </section> <section id="CD001876-sec-0036"> <h5 class="title">Control</h5> <p>Placebo or no adjunctive treatment.</p> <p>Both treatment groups should receive the same antituberculous drug regimen.</p> </section> </section> <section id="CD001876-sec-0037"> <h4 class="title">Types of outcome measures</h4> <section id="CD001876-sec-0038"> <h5 class="title">Short term (under six months)</h5> <p> <ul id="CD001876-list-0001"> <li> <p>Time to resolution of clinical symptoms (as defined by the authors, including fever and pain) </p> </li> <li> <p>Time to resolution of pleural effusion</p> </li> </ul> </p> </section> <section id="CD001876-sec-0039"> <h5 class="title">Long term (six months or more)</h5> <p> <ul id="CD001876-list-0002"> <li> <p>Pleural changes at the end of treatment (pleural thickening and pleural adhesions)</p> </li> <li> <p>Change in respiratory function</p> </li> <li> <p>Disability (as defined by authors)</p> </li> <li> <p>Deaths from any cause</p> </li> </ul> </p> <p>We will also report on other outcomes of resolution as defined by the author.</p> </section> <section id="CD001876-sec-0040"> <h5 class="title">Adverse effects</h5> <p> <ul id="CD001876-list-0003"> <li> <p>Corticosteroid‐associated adverse effects</p> </li> <li> <p>HIV‐associated adverse effects</p> </li> </ul> </p> </section> </section> </section> <section id="CD001876-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD001876-sec-0042"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD001876-sec-0093">Appendix 1</a>: the Cochrane Infectious Diseases Group Specialized Register (18 November 2016); the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (18 November 2016); MEDLINE (1966 to 18 November 2016); Embase (1974 to 18 November 2016); and LILACS (1982 to 18 November 2016). We also searched Current Controlled Trials (18 November 2016) using 'tuberculosis' and 'pleur*' as search terms. </p> </section> <section id="CD001876-sec-0043"> <h4 class="title">Searching other resources</h4> <p>We performed hand searches of the reference lists of all studies identified with the above methods. </p> </section> </section> <section id="CD001876-sec-0044"> <h3 class="title" id="CD001876-sec-0044">Data collection and analysis</h3> <section id="CD001876-sec-0045"> <h4 class="title">Selection of studies</h4> <p>The review authors screened the results of the search for potentially relevant studies. We independently applied eligibility criteria and resolved differences in opinion through discussion. Where the abstracts were unclear or if there was any other reason for uncertainty, we obtained the full‐text article before we made a decision on study eligibility, and we contacted the study authors where necessary. We consulted translators when abstracts were unavailable in English. We assessed the full‐text articles of potentially relevant studies and included trials that met the inclusion criteria. We listed studies that did not meet our inclusion criteria and stated the reason for exclusion in a '<a href="./references#CD001876-sec-0105" title="">Characteristics of excluded studies</a>' table. We constructed a PRISMA diagram to illustrate the study selection process. </p> </section> <section id="CD001876-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (PD and HR) independently extracted data from the included trials on participant characteristics, diagnostic criteria, HIV status, antituberculous drug regimen, corticosteroid regimen, and outcome measures using a pre‐piloted data extraction form. One review author (JY) extracted data from <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> as both trial reports were in Korean. We resolved disagreements through discussion and contacted the corresponding trial author in the case of unclear or missing data. </p> <p>For dichotomous outcomes, we recorded the number of participants that experienced the event and the number of participants in each treatment group. For continuous outcomes, we extracted the arithmetic means and standard deviations for each treatment group together with the numbers of participants in each group. </p> </section> <section id="CD001876-sec-0047"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (PD and HR, or JY and HR) independently assessed the risk of bias for each included trial using the Cochrane 'Risk of bias' tool (<a href="./references#CD001876-bbs2-0048" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions (updated March 2011). The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We resolved any differences of opinion through discussion with reference to the trial reports, and through discussion with the Cochrane Infectious Diseases Group Co‐ordinating Editor, Paul Garner. We followed the guidance to assess whether adequate steps had been taken to reduce the risk of bias across six domains. </p> <p> <ul id="CD001876-list-0004"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessors</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective reporting</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>When assessing risk of bias related to blinding (performance bias or detection bias), we planned to consider the implications of blinding separately for each outcome, as appropriate. </p> <p>For assessment of bias related to incomplete outcome data (attrition bias), we used the following criteria to assess risk of bias. </p> <p> <ul id="CD001876-list-0005"> <li> <p>Low risk: less than 5% of participants were lost to follow‐up</p> </li> <li> <p>Unclear risk: between 5 and 10% of participants were lost to follow‐up</p> </li> <li> <p>High risk: more than 10% of participants were lost to follow‐up</p> </li> </ul> </p> <p>For selective reporting (reporting bias), we used the following criteria to determine the risk of bias. </p> <p> <ul id="CD001876-list-0006"> <li> <p>Low risk: the trial authors stated in the introduction or method sections the outcomes they would look at, and they reported all of them in the results section </p> </li> <li> <p>Unclear risk: the trial authors did not state in the introduction or method sections the outcomes they would look at </p> </li> <li> <p>High risk: the trial authors stated the outcomes they would look at but they did not report all of them in the results section </p> </li> </ul> </p> <p>We categorized these judgments as either at low, high, or unclear risk of bias. We attempted to contact the trial authors for clarification if any details were unclear; where our judgement is recorded as 'unclear' we were unable to amend our judgement after we contacted the trial authors. The results of the 'Risk of bias' assessment are displayed in the '<a href="./references#CD001876-sec-0104" title="">Characteristics of included studies</a>' tables. </p> </section> <section id="CD001876-sec-0048"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we used relative risk as the measure of treatment effect for analysis. For continuous outcomes we planned to use mean difference, but this was not necessary in the final review draft. </p> </section> <section id="CD001876-sec-0049"> <h4 class="title">Unit of analysis issues</h4> <p>There were no cluster‐RCTs amongst the included trials, so individual participants were the unit of analysis. </p> </section> <section id="CD001876-sec-0050"> <h4 class="title">Dealing with missing data</h4> <p>The primary analysis was an intention‐to‐treat analysis where all participants randomized to treatment were included in the denominator, where possible. This analysis assumes that all losses to follow‐up have good outcomes. We planned to explore the effect of losses to follow‐up on the overall effect estimates by performing sensitivity analyses. </p> </section> <section id="CD001876-sec-0051"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by visually inspecting the forest plots to determine closeness of point estimates with each other and overlap of confidence intervals (CIs). We used the Chi² test with a P value of 0.10 to indicate statistical significance, and the I² statistic to assess heterogeneity with a value of 50% taken to indicate statistical heterogeneity. We planned to investigate heterogeneity through the following subgroup analyses: corticosteroid dose, HIV status, and methodological quality. </p> </section> <section id="CD001876-sec-0052"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to look for publication bias by constructing a funnel plot, but there were too few studies to do this. </p> </section> <section id="CD001876-sec-0053"> <h4 class="title">Data synthesis</h4> <p>We analysed the data using Review Manager 5 (RevMan 5) (<a href="./references#CD001876-bbs2-0060" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5</a>). For outcomes where it was possible to combine data and clinical heterogeneity was low, we decided to perform a meta‐analysis. We used risk ratios (RR) with 95% CIs and the fixed‐effect model. For outcomes where it was not possible to combine data, we described the results in tables. We summarized the adverse event data in tables and performed meta‐analysis for adverse events leading to discontinuation of the trial drug, and HIV‐associated adverse events. </p> </section> <section id="CD001876-sec-0054"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where there was substantial unexplained statistical heterogeneity, we carried out subgroup analyses to investigate possible causes. </p> </section> <section id="CD001876-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>To explore the possible effect of losses to follow‐up, we planned to conduct a worst case scenario analysis and compare it with an available‐case analysis for the outcome pleural changes at the end of treatment. There were few losses to follow‐up in the included trials, and the two trials with the highest number of losses to follow‐up did not state which treatment groups these participants were randomized to. Therefore we did not conduct the sensitivity analysis as planned. </p> <section id="CD001876-sec-0056"> <h5 class="title">Quality of the evidence</h5> <p>We assessed the quality of the evidence using the GRADE approach (<a href="./references#CD001876-bbs2-0051" title="JüniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>). We used GRADEpro Guideline Development Tool (GDT) software to construct a 'Summary of findings' table (<a href="./references#CD001876-bbs2-0047" title="GRADE Working Group, McMaster University. GRADEpro Guideline Development Tool (GDT). Version accessed 20 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro GDT 2014</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001876-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001876-sec-0057"></div> <section id="CD001876-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD001876-sec-0059"> <h4 class="title">Results of the search</h4> <p>In the 2007 version of this Cochrane Review, we screened 48 studies, of which we identified 27 published trials for possible inclusion into the review. Six trials met the inclusion criteria (<a href="./references#CD001876-bbs2-0071" title="EngelME , MatchabaPT , VolminkJ . Corticosteroids for tuberculous pleurisy. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD001876.pub2] ">Engel 2007</a>). In this review update, the search returned one new study, which we excluded. <a href="#CD001876-fig-0001">Figure 1</a> shows the study selection process. We have described the characteristics of the included studies in the '<a href="./references#CD001876-sec-0104" title="">Characteristics of included studies</a>' tables and summarized the results in <a href="#CD001876-tbl-0003">Table 2</a>. </p> <div class="figure" id="CD001876-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001876-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <div class="table" id="CD001876-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Year</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adults or children</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ATT regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Therapeutic thoracocentesis performed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1991 to 1994</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2RHZE/7RHE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uganda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 to 2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2RHZE/4RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1985 to 1992</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983 to 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3RHE/6‐9RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990 to 1997</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RHZE or 2RHZS/4RHZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994 to 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RHZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; E: ethambutol; H: isoniazid; R: rifampicin; S: streptomycin; Z: pyrazinamide. </p> </div> </div> </section> <section id="CD001876-sec-0060"> <h4 class="title">Included studies</h4> <section id="CD001876-sec-0061"> <h5 class="title">Settings</h5> <p>The six trials included 633 participants, with a range of 45 to 197 per trial, and were conducted in a various countries: Taiwan (<a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>), Spain (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>), South Africa (<a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), Korea (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>), and Uganda (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). All trials were single centre trials based in large tertiary care hospitals. </p> </section> <section id="CD001876-sec-0062"> <h5 class="title">Participants</h5> <p>All participants were adults except in one trial, <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, which included people aged 11 years and older. All trials included participants of both sexes; overall 59% were male, with a range of 51% to 64% across trials. </p> <p>One trial included only HIV‐positive participants (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>), two trials excluded HIV‐positive participants (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), while the other included trials did not mention the HIV status of the participants. </p> <p>All but one trial, <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, specified the exclusion of participants with co‐morbidities that may be exacerbated by the use of corticosteroids, particularly hypertension, diabetes mellitus, and peptic ulcer disease. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> also specified the exclusion of participants with another major HIV‐related disease. </p> <p>We have described the diagnostic tests performed in each included trial in <a href="#CD001876-tbl-0004">Table 3</a>. Diagnosis of pleural TB was made on the basis of either characteristic histopathological features on pleural biopsy or positive culture or acid‐fast bacilli (AFB) on smear microscopy staining from pleural fluid, biopsy or sputum in three trials (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> also included participants with a diagnosis of tuberculous pleurisy based on a combination of at least two of: reactive Mantoux test, lymphocytic pleural fluid, and raised adenosine deaminase activity in pleural fluid. <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> only included participants who had positive microscopy for AFB from sputum, pleural fluid, or pleural biopsy. <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> included participants with pleural biopsy "reported as pleural tuberculosis or chronic granulomatous inflammation". </p> <div class="table" id="CD001876-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnostic testing in included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnostic criteria for pleural TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other diagnostic tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopy positive for AFB or culture positive from sputum, pleural fluid, or pleural biopsy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0007"> <li> <p>Chest X‐ray</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive culture from pleural biopsy, pleural fluid, or sputum, or histopathologic analysis of pleural biopsy consistent with tuberculous pleurisy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0008"> <li> <p>Chest X‐ray</p> </li> <li> <p>HIV test (rapid test and ELISA)</p> </li> <li> <p>Serum cryptococcal antigen test</p> </li> <li> <p>CD4<sup>+</sup> cell count </p> </li> <li> <p>HIV viral load (plasma and pleural fluid)</p> </li> <li> <p>Serum glucose</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least one of the following</p> <p> <ul id="CD001876-list-0009"> <li> <p>Pleural exudate with positive culture</p> </li> <li> <p>Pleural biopsy culture positive</p> </li> <li> <p>Pleural biopsy with caseating granulomas with Langhans giant cells,</p> </li> <li> <p>Epithelioid cells and lymphocytes</p> </li> <li> <p>Compatible clinico‐radiological picture plus 2 or more of the following:</p> <ul id="CD001876-list-0010"> <li> <p>age &lt; 40 years, PPD &gt; 6 mm or conversion using 5 units of tuberculin PPD‐S, lymphocytic pleural fluid (&gt; 70% lymphocytes), pleural fluid levels of adenosine deaminase activity (ADA) &gt; 60 U/mL </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0011"> <li> <p>Chest X‐ray</p> </li> <li> <p>Simple spirometry (FVC and FEV<sub>1</sub>) </p> </li> <li> <p>Serum biochemistry</p> </li> <li> <p>Full blood count</p> </li> <li> <p>HIV test</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural biopsy reported as pleural TB or chronic granulomatous inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0012"> <li> <p>Chest X‐ray</p> </li> <li> <p>Unspecified diagnostic tests to exclude heart failure, malignancy, pneumonia, diabetes mellitus </p> </li> <li> <p>Chest ultrasound or CT scan in participants with persisting pleural effusion after 3 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TB on pleural biopsy, or pleural effusion <i>plus</i> AFB stain positive or culture positive from sputum, pleural fluid, or pleural biopsy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0013"> <li> <p>Chest X‐ray</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural biopsy with caseating granulomata with or without AFB on histological examination, or positive culture. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0014"> <li> <p>Chest X‐ray</p> </li> <li> <p>Unspecified tests to rule out pneumonia, empyema, malignancy, diabetes mellitus</p> </li> <li> <p>HIV test</p> </li> <li> <p>Thoracoscopy and bronchoscopy performed under general anaesthesia</p> </li> <li> <p>High‐resolution CT chest at three levels to measure pleural thickness</p> </li> <li> <p>Spirometry and body plethysmography</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacilli; CT: computed tomography; ELISA: enzyme‐linked immunosorbent assay; FEV<sub>1</sub>: forced expiratory volume at one second; FVC: forced vital capacity; HIV: human immunodeficiency virus; PPD: purified protein derivative; PPD‐S: purified protein derivative‐standard; TB: tuberculosis </p> </div> </div> </section> <section id="CD001876-sec-0063"> <h5 class="title">Interventions</h5> <p>We have summarized the antituberculous therapy (ATT) regimens used in the included trials in <a href="#CD001876-tbl-0003">Table 2</a>, and the corticosteroid regimens used in <a href="#CD001876-tbl-0005">Table 4</a>. </p> <div class="table" id="CD001876-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Corticosteroid regimens in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regimen</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg twice daily, tapered by 10 mg each week until cessation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily for 2 weeks, 40 mg daily for 2 weeks, then 25 mg daily for 2 weeks, then 15 mg daily for 2 weeks, then stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg/day for 15 days, tapering over the next 15 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg/day, tapered by 5 mg per week until discontinued once radiological improvement was seen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg four times daily for 1 month and tapered over the following month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg/day for 2 to 4 weeks; dose tapered by 5 mg/day over 2 weeks after clinical and radiological improvement </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: mg: milligrams</p> </div> </div> <p>Four trials compared either prednisone or prednisolone with placebo as an adjunct to an established antituberculous regimen containing at least isoniazid and rifampicin (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> did not use any comparative treatment in the control group. </p> <p>Four trials used weight‐based dosing of corticosteroids; <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> started at 1.0 mg/kg twice daily, <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> started at 1.0 mg/kg/day, and <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> and <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> started at 0.75 mg/kg/day. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> started at 50 mg/day for all participants, and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> started at 30 mg four times daily. <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> and <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> tapered the dose of corticosteroid according to the participant's clinical progress; the other included trials either had fixed tapering regimens or did not describe the tapering regimen. </p> <p>All included trials described performing diagnostic pleural aspiration (thoracocentesis) as part of eligibility screening and diagnosis of pleural TB. Two trials also performed therapeutic thoracocentesis (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). In <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, pleural fluid was drained in all participants before discharge "until a third of the hemithorax was observed to be occupied in a standard chest radiograph". In <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>, thoracoscopy and bronchoscopy were performed in all participants under general anaesthesia at admission, and chest drains were left in situ for 48 hours following the procedure to drain remaining pleural fluid. </p> </section> <section id="CD001876-sec-0064"> <h5 class="title">Outcomes</h5> <p>Follow‐up varied from six months to 24 months. Two trials did not clearly state the length of follow‐up (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). </p> <p>None of the included trials reported all the outcome measures chosen for this review.</p> <p>Five trials reported on resolution or improvement of clinical symptoms in some way. <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> and <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> both used self‐reported questionnaires to assess the time until symptom improvement and resolution in all participants; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> asked participants to grade the severity of a range of symptoms on a visual analogue scale. <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> reported the time to resolution of symptoms "including fever, chest pain and dyspnoea" for all participants, but did not specify how this was assessed. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported on improvement of anorexia, weight loss, and cough, but data for other symptoms was not reported. <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> reported on time to resolution of fever. </p> <p>Five trials reported on time to resolution of pleural effusion (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). Four trials reported the number of participants with residual pleural effusion at various time points during treatment (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> and <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> also reported the mean number of days to resolution of pleural effusion. <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> reported the mean reabsorption index for all participants over time. The trial authors calculated the reabsorption index as follows: (length of affected hemithorax/length of healthy hemithorax) x 100. <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> reported recurrence of pleural effusion, rather than time to resolution, as all participants had therapeutic thoracocentesis at the start of treatment. </p> <p>Five trials reported on pleural changes at various time points throughout treatment and at the end of follow‐up (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> and <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> described the diagnostic criteria for pleural thickening on chest X‐ray (<a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> also used high‐resolution computed tomography). Three trials did not describe the criteria for classifying participants as having pleural adhesions or pleural thickening (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). </p> <p>Two trials reported on respiratory function (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). In <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>, spirometry and body plethysmography were performed at admission and at various points during follow‐up. In <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, spirometry was performed at the start and end of treatment. Neither trial reported the complete data for this outcome. </p> <p>Disability was not reported in any of the included trials. Only one trial reported any deaths (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). </p> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported on CD4+ cell count at enrolment to the trial and at 1, 2, 6, and 18 months after start of treatment. A subset of participants (N = 40) also had blood and pleural fluid specimens analysed for HIV viral load. </p> <p>All trials reported adverse events, although there was variation in the level of detail. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported on HIV‐related disease as well as corticosteroid‐related adverse events. </p> </section> </section> <section id="CD001876-sec-0065"> <h4 class="title">Excluded studies</h4> <p>We have listed the reasons for excluding 22 studies in the '<a href="./references#CD001876-sec-0105" title="">Characteristics of excluded studies</a>' section. </p> </section> </section> <section id="CD001876-sec-0066"> <h3 class="title">Risk of bias in included studies</h3> <p>See the '<a href="./references#CD001876-sec-0104" title="">Characteristics of included studies</a>' tables for details of individual included trials. The results of the 'Risk of bias' assessment are summarized in <a href="#CD001876-fig-0002">Figure 2</a> and <a href="#CD001876-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001876-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials." data-id="CD001876-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. </p> </div> </div> </div> <div class="figure" id="CD001876-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial." data-id="CD001876-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial. </p> </div> </div> </div> <section id="CD001876-sec-0067"> <h4 class="title">Allocation</h4> <p>All included trials were reported as randomized. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> explicitly stated that random numbers were computer‐generated, which we considered to be low risk of bias. The other included trials did not indicate how the sequence was generated, and we assessed them as at unclear risk of bias. </p> <p>One trial gave a detailed description of the method of allocation concealment and we assessed it as at low risk of bias; briefly, prednisolone and matching placebo tablets were packaged in identical sequentially numbered plastic bags labelled with the randomization code by two people unrelated to the trial (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). The rest did not describe the method of allocation concealment, and so we classified them as at unclear risk of bias. </p> </section> <section id="CD001876-sec-0068"> <h4 class="title">Blinding</h4> <p>Four trials described blinding of participants and personnel and we assessed them as at low risk of bias (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> did not mention blinding, and therefore we classified them as at unclear risk of bias. </p> <p>Two trials specified blinding of outcome assessors and we assessed them as being at low risk of bias (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). None of the other trials reported whether or not outcome assessors were blinded to treatment allocation, and so we assessed them as at unclear risk of bias. </p> </section> <section id="CD001876-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Three trials did not report any losses to follow‐up (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> excluded one participant in the corticosteroid group from the analysis as the trial drug had to be stopped due to epigastric pain. <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported 3/197 (1.5%) participants lost to follow‐up; one from the placebo group and two from the corticosteroid group. We categorised these trials as at low risk for attrition bias. </p> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> excluded 4/74 (5.4%) from the analysis; three due to noncompliance with treatment and one due to a diagnosis of oesophageal cancer during treatment. The authors do not report which groups the excluded participants were allocated to. We categorised this trial as at unclear risk of attrition bias. </p> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> excluded 5/45 (11.1%) from the analysis; one due to a diagnosis of renal cell carcinoma during treatment, and four were lost to follow‐up. We classified this trial as at high risk of attrition bias. </p> </section> <section id="CD001876-sec-0070"> <h4 class="title">Selective reporting</h4> <p>Trial protocols were unavailable for all of the included trials. Five trials stated the outcomes clearly in the introduction and methods sections of the study reports, and reported all stated outcomes (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). </p> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported that the hypothesis of the trial was that prednisolone would improve long‐term survival, and decrease HIV viral replication, but did not list the planned outcomes. We assessed this trial as at high risk of reporting bias because in the results section it implied that data on resolution of symptoms that did not demonstrate a statistically significant positive effect of prednisolone was not reported, whereas data were reported for the outcomes of anorexia, weight, and cough where a statistically significant positive effect was found. </p> </section> <section id="CD001876-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find enough trials that met the inclusion criteria for us to conduct a funnel plot to look for possible publication bias. </p> </section> </section> <section id="CD001876-sec-0072"> <h3 class="title" id="CD001876-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD001876-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD001876-sec-0073"> <h4 class="title">Time to resolution of clinical symptoms</h4> <p>Due to the different units of measurement used in the trials, and insufficient reported data, it was not possible to combine the effects in a meta‐analysis for this outcome. We have presented the results from the included trials in <a href="#CD001876-tbl-0006">Table 5</a>. Qualitatively, corticosteroids appear to be associated with more rapid resolution of symptoms, but we were unable to assess the relative effect of corticosteroids statistically. </p> <div class="table" id="CD001876-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results: Time to resolution of symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mean values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever, pleuritic pain, malaise and breathlessness”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (N = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4<sup>1</sup> (N = 50) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever duration”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.32 (N = 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.15 (N = 60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever, pleuritic pain, malaise and breathlessness”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (N = 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6 (N = 19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cut‐offs (categorical)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Anorexia”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with anorexia at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/99 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/98 (18.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Cough”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with cough at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/99 (35.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/98 (58.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Weight”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean weight in kg at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved in all patients (VAS score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: kg: kilograms; VAS: visual analogue scale<br/> <sup>1</sup>P &lt; 0.05. </p> </div> </div> </section> <section id="CD001876-sec-0074"> <h4 class="title">Time to resolution of pleural effusion</h4> <p>Five trials reported on time to resolution of pleural effusion (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). We combined data for the number of participants with a residual pleural effusion on chest X‐ray in each treatment group from four trials. <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>, <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004,</a> and <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> reported data across three time points (4 weeks, 8 weeks, and 24 weeks), and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> reported data for two time points (8 weeks and 24 weeks). <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> presented the mean reabsorption index for each treatment group at four weeks, and so we could not use data from this trial in the meta‐analysis. We have presented the results from each trial in <a href="#CD001876-tbl-0007">Table 6</a>. <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> reported on recurrence of pleural effusion, as all participants had drainage of their pleural effusions at admission to the trial, and reported no recurrences of pleural effusion in either group. </p> <div class="table" id="CD001876-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to resolution of pleural effusion on chest X‐ray</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mean values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (N=34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (N=50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5 (N=21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123.2 (N=19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reabsorption index<sup>1</sup> at 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><b>Categorical values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/34 (76.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/50 (78%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/34 (55.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/50 (60%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/34 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/50 (6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/99 (38.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/98 (57.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/99 (30.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/98 (56.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/99 (10.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/98 (25.5%)<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/21 (42.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/19 (78.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/21 (23.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/19 (63.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/19 (31.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/32 (90.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/50 (98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/32 (62.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/50 (88%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: N: number of participants<br/> <sup>1</sup>Reabsorption index = (length of affected hemithorax/length of healthy hemithorax) x 100.<br/> <sup>2</sup>P = 0.01.<br/> <sup>3</sup>Data at this time point extrapolated from graph. Data for 4 weeks and 8 weeks from the trial authors (unpublished data). </p> </div> </div> <p>The initial meta‐analysis, which includes data from <a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>, <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>, <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>, and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>, found substantial statistical heterogeneity at all three time points, and we conducted a subgroup analysis to explore this (<a href="./references#CD001876-fig-0009" title="">Analysis 2.1</a>; <a href="./references#CD001876-fig-0010" title="">Analysis 2.2</a>). When we excluded trials that were at high risk of bias for selection bias (randomization and allocation concealment) from the meta‐analysis, the statistical heterogeneity resolved. In these two trials it is possible that the trial investigators allocated a greater proportion of participants with more severe pleural effusions to the corticosteroid group, believing that corticosteroids would be of benefit to them (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). This would lead to bias towards the null, and a misleading summary effects estimate. For this reason, we excluded the trials that were at high risk of selection bias from the meta‐analysis. </p> <p>The results showed a reduction in the risk of having residual pleural fluid on chest X‐ray at all three time points in participants treated with corticosteroids: by 36% at four weeks (RR 0.64, 95% CI 0.49 to 0.84; 237 participants, 2 trials), 45% at eight weeks (RR 0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials), and 65% at 24 weeks (RR 0.35, 95% CI 0.18 to 0.66; 237 participants, 2 trials). </p> </section> <section id="CD001876-sec-0075"> <h4 class="title">Pleural changes on chest X‐ray at the end of treatment</h4> <p>Five trials reported on chest X‐ray changes to the pleura at the end of treatment (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). The terms 'pleural thickening' and 'pleural adhesions' were used to describe these changes, and in some cases seemed to be used interchangeably. We found that corticosteroids may reduce the risk of having pleural changes on chest X‐ray after at least six months by 28% (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials, <i>low certainty evidence</i>; <a href="./references#CD001876-fig-0005" title="">Analysis 1.2</a>). </p> <p>One trial, <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, attempted to quantify the degree of pleural thickening by measuring the maximal pleural thickening in millimetres at 1, 6, and 12 months after enrolment, and reported the mean maximal pleural thickness for each treatment group. The prednisolone group had a mean maximal pleural thickness of 1.77 mm (range 0 to 40 mm), and for the placebo group 2.23 mm (0 to 15 mm), with a P value of more than 0.05. </p> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> also performed high resolution CT scan of the chest in most participants, and found 17/32 participants in the prednisolone group and 21/35 participants in the placebo group had pleural thickening at the end of treatment using this test (P = 0.52). </p> <p>None of the included trials looked at the extent of pleural changes on chest X‐ray in terms of area of pleural change. </p> </section> <section id="CD001876-sec-0076"> <h4 class="title">Change in respiratory function</h4> <p>Two trials with 191 participants measured improvement in respiratory function and found no difference between the groups (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). We have summarized the results in <a href="#CD001876-tbl-0008">Table 7</a>. </p> <div class="table" id="CD001876-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Pulmonary function at the end of treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (N = 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (N = 60)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85% (N = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% (N = 36)<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with restrictive PFT results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/34 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/36 (39.4%)<sup>3</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: FVC: forced vital capacity; N: number of participants; PFT: pulmonary function tests<br/> <sup>1</sup>Range 65% to 130% in steroid group, 63% to 140% in placebo group.<br/> <sup>2</sup>Read from graph, P = 0.65.<br/> <sup>3</sup>P = 0.72. Results extrapolated from percentages. </p> </div> </div> <p>In <a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, mean forced vital capacity (FVC) was 95% in both the treatment and control groups at the end of treatment; in <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> it was 85% in the corticosteroids group and 80% in the placebo group (P = 0.65). We could not perform a meta‐analysis due to insufficient reported data. </p> </section> <section id="CD001876-sec-0077"> <h4 class="title">Disability</h4> <p>None of the included trials looked at disability or functional impairment after treatment for TB pleurisy. </p> </section> <section id="CD001876-sec-0078"> <h4 class="title">Death from any cause</h4> <p>Only <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported any deaths, with 36/99 deaths in the prednisolone group, and 39/98 deaths in the placebo group, meaning the relative risk of death in the prednisolone group was 0.91 (95% CI 0.64 to 1.31; 197 participants, 1 trial; <a href="./references#CD001876-fig-0006" title="">Analysis 1.3</a>), which indicated that prednisolone did not confer a survival benefit. The trial authors commented that mortality rates were higher in participants with low CD4+ cell counts on enrolment to the trial. </p> </section> <section id="CD001876-sec-0079"> <h4 class="title">Adverse effects of treatment</h4> <p>More participants in the corticosteroid group had adverse events leading to discontinuation of the study drug (RR 2.78, 95% CI 1.11 to 6.94; 590 participants, 6 trials, <i>low certainty evidence</i>; <a href="./references#CD001876-fig-0007" title="">Analysis 1.4</a>). We have summarized the results in <a href="#CD001876-tbl-0009">Table 8</a>. </p> <div class="table" id="CD001876-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events leading to discontinuation of the trial drug</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/99 (9.1%)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/98 (2.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21 (4.8%)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/34 (11.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36 (8.3%)<sup>4</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: NR: not reported</p> <p><sup>1</sup>Aggravation of epigastric pain in one patient, steroids stopped, and patient withdrawn from the trial.<br/> <sup>2</sup>Trial drug discontinued for hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants), oesophageal candidiasis (one participant) in the corticosteroid group; in the placebo group hyperglycaemia (one participant) and hypertension (one participant).<br/> <sup>3</sup>One participant developed moon facies, epigastric pain, and lower limb oedema, all of which resolved on tapering the dosage.<br/> <sup>4</sup>Epigastric pain was the only adverse effect noted, and affected four participants in the steroid group and three in the control group. </p> </div> </div> <p>There was variation in the level of detail reported across the different trials, and assessment of participants to detect adverse effects of treatment also varied. </p> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> reported one participant from the corticosteroid group was withdrawn from the study due to aggravation of epigastric pain. </p> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> reported one participant from the corticosteroid group developed moon‐shaped face, epigastric pain, and lower limb oedema which resolved on tapering the study drug. </p> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> reported that the only adverse effect observed was epigastric pain, which affected 4/34 participants in the corticosteroid group and 3/36 participants in the placebo group. </p> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> reported 9/99 participants in the corticosteroid group stopped the trial drug due to hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants), or oesophageal candidiasis (one participant). In the placebo group 2/98 participants stopped the trial drug; one participant due to hyperglycaemia and one participant due to hypertension. </p> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> reported no adverse events in either treatment group, and <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> reported no significant adverse events in the participants treated with steroids. </p> </section> <section id="CD001876-sec-0080"> <h4 class="title">HIV‐associated adverse events</h4> <p>Only <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> included HIV‐positive participants. The trial reported adverse events related to HIV, including candidiasis, herpes simplex and herpes zoster, cryptococcal meningitis, gastroenteritis, and Kaposi's sarcoma (summarized in <a href="#CD001876-tbl-0010">Table 9</a>). For most of these adverse events there was no difference between the corticosteroid and placebo groups. For Kaposi's sarcoma, there was a statistically non‐significant trend towards increased risk with corticosteroids: 6/99 in the corticosteroid group developed Kaposi's sarcoma compared with 0/98 in the placebo group (RR 12.87, 95% CI 0.73 to 225.40; 197 participants, 1 trial, <i>very low certainty evidence</i>). </p> <div class="table" id="CD001876-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Results: HIV‐related adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control (N/98)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroid (N/99)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kaposi’s sarcoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (6.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cryptococcal meningitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (5.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (3.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (23.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (35.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (32.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (31.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herpes zoster</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (19.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (22.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral or genital herpes simplex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (20.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (22.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (28.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (34.3%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: N: number of participants</p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001876-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001876-sec-0081"></div> <section id="CD001876-sec-0082"> <h3 class="title" id="CD001876-sec-0082">Summary of main results</h3> <p>See 'Summary of findings' table 1 (<a href="./full#CD001876-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>Six trials met the inclusion criteria; we have not included any new trials since the 2007 version of this Cochrane Review (<a href="./references#CD001876-bbs2-0071" title="EngelME , MatchabaPT , VolminkJ . Corticosteroids for tuberculous pleurisy. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD001876.pub2] ">Engel 2007</a>), and we did not find any trials in progress that address this question. </p> <p>There was a trend towards faster resolution of symptoms, such as fever and chest pain, with corticosteroids across all included trials, but the trials reported insufficient data to produce a meta‐analysis addressing time to resolution of symptoms, and there were variations across studies in terms of which symptoms were reported and who the participants were monitored and assessed. </p> <p>Corticosteroids probably reduce the time to resolution of pleural effusion.</p> <p>Corticosteroids may reduce risk of pleural changes on chest X‐ray at the end of treatment by 28% (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials, <i>low certainty evidence</i>). On average, half the participants in the control group had pleural changes at the end of at least six months, giving an estimated absolute risk reduction of 14% with corticosteroids. </p> <p>There was insufficient data to draw conclusions about the effect of corticosteroids on respiratory function after treatment, and none of the included trials reported on disability after treatment. Only one trial reported on death (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>), and the trial authors' analysis suggests that death was related to low CD4+ cell counts, which implied that death was related to severity of HIV disease. Corticosteroids had no effect on all‐cause mortality in this trial (RR 0.91, 95% CI 0.64 to 1.31; 197 participants, 1 trial). </p> <p>Corticosteroids may increase risk of adverse events leading to discontinuation of the study drug (RR 2.78, 95% CI 1.11 to 6.94; 587 participants, 6 trials, <i>low certainty evidence</i>). Commonly reported adverse effects included epigastric pain, hypertension, and hyperglycaemia. </p> <p>Only one trial included HIV‐positive people and reported on HIV‐associated adverse events (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). While there was no significant difference between the corticosteroid and placebo groups for any of the conditions observed, Kaposi's sarcoma was only observed in the group receiving steroids: 6/99 in the corticosteroid group developed Kaposi's sarcoma compared with 0/98 in the placebo group (RR 12.87, 95% CI 0.73 to 225.40; 197 participants, 1 trial, <i>very low certainty evidence</i>). </p> </section> <section id="CD001876-sec-0083"> <h3 class="title" id="CD001876-sec-0083">Overall completeness and applicability of evidence</h3> <p>The six trials included male and female participants, who were mostly HIV‐negative adults. One trial included children over the age of 11 years (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>), and one trial included only HIV‐positive adults (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). The trials reflected the fact that pleural TB is more common in adults, but HIV‐positive people are under‐represented in this review, and the results of the pooled estimates may be less applicable to HIV‐positive people. The included trials were all conducted in tertiary hospital settings, in a countries varying from low to high TB burden and HIV prevalence. </p> <p>The method of diagnosis of pleural TB varied between the included trials (see <a href="#CD001876-tbl-0004">Table 3</a>), but were representative of diagnostic tests commonly available in high‐ and middle‐income settings. Culture and histopathology are less accessible in low‐income settings, where diagnosis may be based on clinical presentation and X‐ray findings alone. </p> <p>The antituberculous treatment (ATT) that participants received varied across the included trials, and in some trials the treatment given was significantly different from widely recommended first‐line treatment for drug‐sensitive TB (see <a href="#CD001876-tbl-0003">Table 2</a>). Most notably, the older trials included either two drugs (<a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>), or three drugs (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), in their regimens rather than all four currently recommended first‐line drugs in the intensive phase of treatment. Participants were given at least six months of ATT in all trials. This variation in ATT was not associated with statistically significant heterogeneity in any of our analyses. As the more recent trials used regimens that are the same or very similar to currently recommended regimens for drug‐sensitive TB, it is unlikely that the variation in ATT regimens between the trials limits the applicability of the evidence. </p> <p>For some outcomes, such as respiratory function and time to resolution of symptoms, incomplete reporting of data and differences in units meant that we could not combine data to generate a summary effects estimate. </p> </section> <section id="CD001876-sec-0084"> <h3 class="title" id="CD001876-sec-0084">Quality of the evidence</h3> <p>We assessed the quality of the evidence using the GRADE approach (<a href="./references#CD001876-bbs2-0051" title="JüniP , AltmanDG , EggerM . Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001;323(7303):42‐6. ">Jüni 2001</a>), and reported the outcomes in a 'Summary of findings' table (<a href="./full#CD001876-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>For time to resolution of pleural effusion, we combined data on residual pleural fluid on chest X‐ray from four trials. As described in the results section, after exploring high unexplained statistical heterogeneity for this outcome, we chose to exclude the two trials that were at high risk of selection bias from the final analysis to avoid a misleading summary estimate of effect. The exclusion of studies from the meta analysis generates uncertainty, and therefore we chose to downgrade by one because of this. We also downgraded for imprecision; the number of participants and events is small, the meta analysis is probably underpowered. </p> <p>We graded the summary effects estimate for pleural changes at the end of treatment as low certainty evidence, and downgraded due to concerns about risk of bias relating to randomization and allocation methods, and for imprecision relating to the relatively small number of events and participants. </p> <p>For long‐term functional respiratory impairment, we graded the quality of the evidence as very low. Meta‐analysis was not possible for this outcome due to insufficient reporting of data, and we reported the available data in <a href="#CD001876-tbl-0008">Table 7</a>. Although two trials reported the mean percentage predicted forced vital capacity (FVC) at the end of treatment (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>, <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), neither the results per participant nor the variance were reported. </p> <p>For adverse events leading to discontinuation of the trial drug, we assessed the quality of the evidence as low. We downgraded for risk of bias relating to randomization and allocation concealment, and also reporting as some trials did not report on adverse events in detail. Also a few only referred to adverse effects associated with steroids in the steroid group, which raised the concern that adverse events in the control group were not detected or reported. </p> <p>For adverse events relating to HIV, we graded the estimates of effect relating to two serious, life‐threatening HIV‐related diseases — cryptococcal meningitis and Kaposi's sarcoma — and judged the quality of the evidence to be very low. We downgraded by two for imprecision caused by the small number of events and participants, and also by one for indirectness as the participants were all from one single‐centre trial and none were on antiretroviral therapy. These estimates of effect may not be applicable to HIV‐positive people in other settings or those taking antiretroviral therapy. </p> </section> <section id="CD001876-sec-0085"> <h3 class="title" id="CD001876-sec-0085">Potential biases in the review process</h3> <p>We attempted to limit bias in the review process. Vittoria Lutje, the Cochrane Infectious Diseases Group Information Specialist, conducted the literature searches, and it is unlikely that these searches missed any major trials; however, we cannot rule out the possibility that we missed some small unpublished trials. The funnel plot did not assist with this because there were too few included trials. To limit bias in the trial selection process and data extraction, we independently examined the search results, determined study selection, and extracted data. </p> </section> <section id="CD001876-sec-0086"> <h3 class="title" id="CD001876-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>There are relatively few studies and reviews on this topic in the literature. We could find no other systematic reviews that address this question. <a href="./references#CD001876-bbs2-0039" title="ChapmanSJ , DaviesRJ . The management of pleural space infections. Respirology2004;9(1):4‐11. ">Chapman 2004</a>, a narrative review of the diagnosis and management of pleural space infection, comments that the role of steroids is uncertain as study findings are conflicting, and do not provide information about the effect of steroids on long‐term lung function and mortality. Another narrative review, <a href="./references#CD001876-bbs2-0045" title="FerreiroL , San JoséE , ValdésL . Tuberculous Pleural Effusion. Archivos de Bronconeumologia2014;50(10):435‐43. ">Ferreiro 2014</a>, drew similar conclusions, and noted that the conflicting results between studies and the possibility raised by <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> that use of corticosteroids in HIV‐positive patients with TB pleurisy may lead to increased risk of Kaposi's sarcoma. <a href="./references#CD001876-bbs2-0052" title="KadhiravanT , DeepanjaliS . Role of corticosteroids in the treatment of tuberculosis: an evidence‐based update. Indian Journal of Chest Diseases and Allied Sciences2010;52(3):153‐8. ">Kadhiravan 2010</a> commented on the previous version of this review (<a href="./references#CD001876-bbs2-0071" title="EngelME , MatchabaPT , VolminkJ . Corticosteroids for tuberculous pleurisy. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD001876.pub2] ">Engel 2007</a>), and noted that while there appears to be an effect of corticosteroids on pleural thickening, the available evidence does not show an effect on lung function. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001876-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001876-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials." data-id="CD001876-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial." data-id="CD001876-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 1 Residual pleural effusion on chest X‐ray." data-id="CD001876-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 1 Residual pleural effusion on chest X‐ray. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 2 Pleural changes at the end of treatment (pleural thickening and pleural adhesions)." data-id="CD001876-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 2 Pleural changes at the end of treatment (pleural thickening and pleural adhesions). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 3 Death from any cause." data-id="CD001876-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 3 Death from any cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 4 Adverse events leading to study drug discontinuation." data-id="CD001876-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 4 Adverse events leading to study drug discontinuation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 5 HIV‐associated adverse events." data-id="CD001876-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus control (placebo or no steroids), Outcome 5 HIV‐associated adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Effect of study quality on the outcome residual pleural fluid on chest X‐ray, Outcome 1 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias excluded." data-id="CD001876-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Effect of study quality on the outcome residual pleural fluid on chest X‐ray, Outcome 1 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias excluded. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001876-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/urn:x-wiley:14651858:media:CD001876:CD001876-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_t/tCD001876-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Effect of study quality on the outcome residual pleural fluid on chest X‐ray, Outcome 2 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias included." data-id="CD001876-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Effect of study quality on the outcome residual pleural fluid on chest X‐ray, Outcome 2 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias included. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/media/CDSR/CD001876/image_n/nCD001876-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001876-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Steroids compared with placebo for pleural TB</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and adolescents with pleural TB </p> <p><b>Settings:</b> hospital care and community follow‐up </p> <p><b>Intervention:</b> corticosteroids </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks¹ (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual pleural fluid on chest X‐ray at 8 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 100</b> </p> <p>(23 to 48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.54 </p> <p>(0.37 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2,3,4</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Residual pleural fluid on chest X‐ray at 24 weeks</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 100</b> </p> <p>(5 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.35 </p> <p>(0.18 to 0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>1,2,3,4</sup> </p> <p><b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pleural changes at the end of follow‐up</b> </p> <p>(pleural adhesions or pleural thickening on chest X‐ray; follow‐up 6 to 24 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 100</b> </p> <p>(29 to 46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.72 </p> <p>(0.57 to 0.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>393</p> <p>(5 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>5,6,7</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Long‐term functional respiratory impairment (&gt; 6 months)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Average percentage predicted FVC similar in corticosteroid and control groups.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187</p> <p>(2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>8</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events leading to treatment discontinuation</b> </p> <p>(follow‐up 6 to 24 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> <br/> (1 to 7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 2.78 </p> <p>(1.11 to 6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>590<br/> (6 trials) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>9,10</sup> <br/> <b>low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV‐related infections (cryptococcal meningitis)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 100</b> </p> <p>(1 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 0.59 </p> <p>(0.15 to 2.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>11,12</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HIV‐related cancer (Kaposi's sarcoma)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b><sup>13</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> <p>(1 to 316)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR</b> 12.87 </p> <p>(0.73 to 225.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> <p>(1 trial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>14,15</sup> <br/> <b>very low</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>¹The basis for the <b>assumed risk</b> (for example, the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>Abbreviations:</b> CI: confidence interval; GRADE: Grading of Recommendations Assessment, Development and Evaluation; RR: risk ratio; TB: tuberculosis; FVC: forced vital capacity. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one for risk of bias: of the four trials that reported this outcome, we excluded two trials from the final analysis due to high risk of selection bias, after a subgroup analysis suggested the pooled estimate including these studies could be misleading (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>). We judged this to be our best estimate of effect. However because we excluded trials from this analysis this generates uncertainty, so we have downgraded the quality of the evidence.<br/> <sup>2</sup>Not downgraded for inconsistency: heterogeneity in the original meta‐analysis was likely due to differences in study quality. A subgroup analysis showed that statistical heterogeneity disappeared when we excluded trials that were at high risk of selection bias.<br/> <sup>3</sup>Downgraded by one for imprecision: the CI around the summary effect estimate is wide due to the small number of participants and events in each included trial.<br/> <sup>4</sup>Not downgraded for indirectness: the included trials were performed in different settings and time periods and used widely available drugs and diagnostic techniques. Although the trials did not include children, we did not downgrade as pleural TB is less common in children than in adults. One trial included HIV‐positive people, <a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>, and this trial contributed most of the participants in the meta‐analysis. When making recommendations relating to the use of corticosteroids for pleural TB in children or in HIV‐negative adults, guideline panels may wish to consider downgrading for indirectness.<br/> <sup>5</sup>Downgraded by one for serious risk of bias: we assessed two trials as at high risk of bias for randomization method (<a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a>; <a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a>), and the other three trials were at unclear risk of bias (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>). Only <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> reported that outcome assessors were blinded to the treatment allocation.<br/> <sup>6</sup>Downgraded by one for serious imprecision: the CI around the summary effect estimate is wide, ranging from a maximum risk reduction with steroids of 43% to a minimum risk reduction of 7%, which may not be clinically significant when weighed against possible harms of steroids.<br/> <sup>7</sup>Not downgraded for indirectness: the trials were performed in a variety of settings, and all used drugs and diagnostic techniques that are widely available. We did not include any HIV‐positive people in this meta‐analysis, so when making recommendations regarding the use of corticosteroids in HIV‐positive people with TB pleurisy, guideline panels may wish to consider downgrading for indirectness. Only one trial included children aged over 11 years of age (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>), but we did not downgrade as pleural TB is not common in children.<br/> <sup>8</sup>Two of the six trials reported pulmonary function tests at the end of treatment (<a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a>; <a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a>), but data were insufficient to combine these outcomes in a meta‐analysis. The data are in <a href="#CD001876-tbl-0008">Table 7</a>, and suggest that in these trials there was little or no difference in mean percentage predicted FVC at the end of treatment. The number of participants in each group with pulmonary function tests suggestive of a functional respiratory impairment are not reported.<br/> <sup>9</sup>Downgraded by one for risk of bias: there were concerns about randomization method and allocation concealment. Additionally, reporting of adverse events varied significantly across the trials, and some trials only reported on adverse events in the steroid group, and it is likely that some trials did not detect or report all adverse events.<br/> <sup>10</sup>Downgraded by one for serious imprecision: the CI around the summary effect estimate is wide, with a maximum increased risk of adverse effects leading to study drug discontinuation of nearly 700% and a minimum increased risk of 12%, which may not be clinically significant when weighed against possible benefits of steroids.<br/> <sup>11</sup>Downgraded by two for serious imprecision: the CI around the summary effect estimate is very wide, and possible effects range from large benefits to significant harms.<br/> <sup>12</sup>Downgraded by one for indirectness: only one trial included HIV‐positive people and assessed HIV‐related adverse events (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). Participants in this trial were not treated with antiretroviral therapy, which is known to prevent cryptococcal meningitis in HIV‐positive people; therefore this estimate may not be applicable to HIV‐positive people on antiretroviral therapy. This trial did not include any children.<br/> <sup>13</sup>Prevalence of Kaposi's sarcoma of 1.4% in HIV‐positive adults on clinic enrolment taken from <a href="./references#CD001876-bbs2-0063" title="SemeereA , WengerM , BusakhalaN , BuzibaN , BwanaM , MuyindikeW , et al. A prospective ascertainment of cancer incidence in sub‐Saharan Africa: the case of Kaposi sarcoma. Cancer Medicine2016;5(5):914‐28. ">Semeere 2016</a>, a multi‐centre prospective cohort study performed in Uganda and Kenya.<br/> <sup>14</sup>Downgraded by two for serious imprecision: the CI around the summary effect estimate is very wide, and possible effects range from large benefits to significant harms.<br/> <sup>15</sup>Downgraded by one for indirectness: only one trial included HIV‐positive people and assessed HIV‐related adverse events (<a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a>). Participants in this trial were not treated with antiretroviral therapy, which is known to treat and prevent Kaposi's sarcoma in HIV‐positive people, therefore this estimate may not be applicable to HIV‐positive people on antiretroviral therapy. This trial did not include any children. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Theoretical framework describing differences between isolated tuberculous pleurisy and pulmonary TB with tuberculous pleurisy (pleuro‐pulmonary TB)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical Feature</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Isolated pleural TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pleuro‐pulmonary TB</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sputum microscopy/culture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Some positive</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural fluid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usually demonstrates exudative effusion</p> <p>Usually negative for <i>M. tuberculosis</i> on smear and culture </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Usually demonstrates exudative effusion</p> <p>Usually negative for <i>M. tuberculosis</i> on smear and culture </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest X‐ray</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discrete pleural effusion, or pleural thickening, or both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural effusion with other changes such as consolidation, cavities, atelectasis, or hilar enlargement </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest computed tomography (CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>May demonstrate underlying lung infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demonstrates underlying lung infection</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pathogenesis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predominantly driven by delayed type hypersensitivity reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Predominantly driven by TB infection of the lung</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prognosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most people will improve with no antituberculous treatment (ATT), but may experience a relapse of TB infection </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People may deteriorate and die without ATT</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Theoretical framework describing differences between isolated tuberculous pleurisy and pulmonary TB with tuberculous pleurisy (pleuro‐pulmonary TB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Country</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Year</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adults or children</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HIV status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>ATT regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Therapeutic thoracocentesis performed</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control group</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1991 to 1994</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2RHZE/7RHE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uganda</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1998 to 2002</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2RHZE/4RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1985 to 1992</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taiwan</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1983 to 1987</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3RHE/6‐9RH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Korea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990 to 1997</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RHZE or 2RHZS/4RHZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>South Africa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1994 to 1995</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adults</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6RHZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Abbreviations: ATT: antituberculous treatment; E: ethambutol; H: isoniazid; R: rifampicin; S: streptomycin; Z: pyrazinamide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnostic testing in included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diagnostic criteria for pleural TB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other diagnostic tests</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopy positive for AFB or culture positive from sputum, pleural fluid, or pleural biopsy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0007"> <li> <p>Chest X‐ray</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive culture from pleural biopsy, pleural fluid, or sputum, or histopathologic analysis of pleural biopsy consistent with tuberculous pleurisy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0008"> <li> <p>Chest X‐ray</p> </li> <li> <p>HIV test (rapid test and ELISA)</p> </li> <li> <p>Serum cryptococcal antigen test</p> </li> <li> <p>CD4<sup>+</sup> cell count </p> </li> <li> <p>HIV viral load (plasma and pleural fluid)</p> </li> <li> <p>Serum glucose</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least one of the following</p> <p> <ul id="CD001876-list-0009"> <li> <p>Pleural exudate with positive culture</p> </li> <li> <p>Pleural biopsy culture positive</p> </li> <li> <p>Pleural biopsy with caseating granulomas with Langhans giant cells,</p> </li> <li> <p>Epithelioid cells and lymphocytes</p> </li> <li> <p>Compatible clinico‐radiological picture plus 2 or more of the following:</p> <ul id="CD001876-list-0010"> <li> <p>age &lt; 40 years, PPD &gt; 6 mm or conversion using 5 units of tuberculin PPD‐S, lymphocytic pleural fluid (&gt; 70% lymphocytes), pleural fluid levels of adenosine deaminase activity (ADA) &gt; 60 U/mL </p> </li> </ul> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0011"> <li> <p>Chest X‐ray</p> </li> <li> <p>Simple spirometry (FVC and FEV<sub>1</sub>) </p> </li> <li> <p>Serum biochemistry</p> </li> <li> <p>Full blood count</p> </li> <li> <p>HIV test</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural biopsy reported as pleural TB or chronic granulomatous inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0012"> <li> <p>Chest X‐ray</p> </li> <li> <p>Unspecified diagnostic tests to exclude heart failure, malignancy, pneumonia, diabetes mellitus </p> </li> <li> <p>Chest ultrasound or CT scan in participants with persisting pleural effusion after 3 months </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TB on pleural biopsy, or pleural effusion <i>plus</i> AFB stain positive or culture positive from sputum, pleural fluid, or pleural biopsy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0013"> <li> <p>Chest X‐ray</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pleural biopsy with caseating granulomata with or without AFB on histological examination, or positive culture. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD001876-list-0014"> <li> <p>Chest X‐ray</p> </li> <li> <p>Unspecified tests to rule out pneumonia, empyema, malignancy, diabetes mellitus</p> </li> <li> <p>HIV test</p> </li> <li> <p>Thoracoscopy and bronchoscopy performed under general anaesthesia</p> </li> <li> <p>High‐resolution CT chest at three levels to measure pleural thickness</p> </li> <li> <p>Spirometry and body plethysmography</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: ADA: adenosine deaminase activity; AFB: acid‐fast bacilli; CT: computed tomography; ELISA: enzyme‐linked immunosorbent assay; FEV<sub>1</sub>: forced expiratory volume at one second; FVC: forced vital capacity; HIV: human immunodeficiency virus; PPD: purified protein derivative; PPD‐S: purified protein derivative‐standard; TB: tuberculosis </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Diagnostic testing in included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Corticosteroid regimens in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Steroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Regimen</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg twice daily, tapered by 10 mg each week until cessation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 mg daily for 2 weeks, 40 mg daily for 2 weeks, then 25 mg daily for 2 weeks, then 15 mg daily for 2 weeks, then stopped </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 mg/kg/day for 15 days, tapering over the next 15 days</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg/day, tapered by 5 mg per week until discontinued once radiological improvement was seen </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 mg four times daily for 1 month and tapered over the following month</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75 mg/kg/day for 2 to 4 weeks; dose tapered by 5 mg/day over 2 weeks after clinical and radiological improvement </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: mg: milligrams</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Corticosteroid regimens in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results: Time to resolution of symptoms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mean values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever, pleuritic pain, malaise and breathlessness”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (N = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4<sup>1</sup> (N = 50) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever duration”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.32 (N = 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.15 (N = 60)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Fever, pleuritic pain, malaise and breathlessness”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4 (N = 21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.6 (N = 19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Cut‐offs (categorical)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Anorexia”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with anorexia at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/99 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/98 (18.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Cough”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with cough at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/99 (35.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57/98 (58.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>“Weight”</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean weight in kg at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptoms resolved in all patients (VAS score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>Abbreviations: kg: kilograms; VAS: visual analogue scale<br/> <sup>1</sup>P &lt; 0.05. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Results: Time to resolution of symptoms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to resolution of pleural effusion on chest X‐ray</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Mean values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 (N=34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 (N=50)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean days to resolution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.5 (N=21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123.2 (N=19)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reabsorption index<sup>1</sup> at 4 weeks </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89%<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="11" valign="top"> <p><b>Categorical values</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/34 (76.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/50 (78%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/34 (55.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/50 (60%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/34 (5.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/50 (6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38/99 (38.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56/98 (57.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/99 (30.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/98 (56.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/99 (10.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/98 (25.5%)<sup>3</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/21 (42.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/19 (78.9%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/21 (23.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/19 (63.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21 (4.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/19 (31.6%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/32 (90.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49/50 (98%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with residual effusion at 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/32 (62.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44/50 (88%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Abbreviations: N: number of participants<br/> <sup>1</sup>Reabsorption index = (length of affected hemithorax/length of healthy hemithorax) x 100.<br/> <sup>2</sup>P = 0.01.<br/> <sup>3</sup>Data at this time point extrapolated from graph. Data for 4 weeks and 8 weeks from the trial authors (unpublished data). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Time to resolution of pleural effusion on chest X‐ray</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Pulmonary function at the end of treatment</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Units</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (N = 57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95% (N = 60)<sup>1</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean percentage predicted FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85% (N = 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% (N = 36)<sup>2</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lung function impairment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with restrictive PFT results</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/34 (33.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/36 (39.4%)<sup>3</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Abbreviations: FVC: forced vital capacity; N: number of participants; PFT: pulmonary function tests<br/> <sup>1</sup>Range 65% to 130% in steroid group, 63% to 140% in placebo group.<br/> <sup>2</sup>Read from graph, P = 0.65.<br/> <sup>3</sup>P = 0.72. Results extrapolated from percentages. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Pulmonary function at the end of treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events leading to discontinuation of the trial drug</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0001" title="BangJS , KimMS , KwakSM , ChoCH . Evaluation of steroid therapy in tuberculous pleurisy ‐ a prospective, randomized study. Tuberculosis and Respiratory Disease1997;44(1):52‐8. ">Bang 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34 (2.9%)<sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/99 (9.1%)<sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/98 (2.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0003" title="GalarzaI , CañeteC , GranadosA , EstopàR , ManresaF . Randomised trial of corticosteroids in the treatment of tuberculous pleurisy. Thorax1995;50(12):1305‐7. ">Galarza 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0004" title="LeeCH , WangWJ , LanRS , TsaiYH , ChiangYC . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1988;94(6):1256‐9. ">Lee 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/21 (4.8%)<sup>3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0005" title="LeeBH , JeeHS , ChoiJC , ParkYB , AnCH , KimJY , et al. Therapeutic effect of prednisolone in tuberculous pleurisy ‐ a prospective study for the prevention of the pleural adhesion. Tuberculosis and Respiratory Disease1999;46(4):481‐8. ">Lee 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001876-bbs2-0006" title="WyserC , WalzlG , SmedemaJP , SwartF , vanSchalkwykEM , van deWalBW . Corticosteroids in the treatment of tuberculous pleurisy. A double‐blind, placebo‐controlled, randomized study. Chest1996;110(2):333‐8. ">Wyser 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/34 (11.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/36 (8.3%)<sup>4</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Abbreviations: NR: not reported</p> <p><sup>1</sup>Aggravation of epigastric pain in one patient, steroids stopped, and patient withdrawn from the trial.<br/> <sup>2</sup>Trial drug discontinued for hyperglycaemia (two participants), hypertension (three participants), herpes zoster (three participants), oesophageal candidiasis (one participant) in the corticosteroid group; in the placebo group hyperglycaemia (one participant) and hypertension (one participant).<br/> <sup>3</sup>One participant developed moon facies, epigastric pain, and lower limb oedema, all of which resolved on tapering the dosage.<br/> <sup>4</sup>Epigastric pain was the only adverse effect noted, and affected four participants in the steroid group and three in the control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Adverse events leading to discontinuation of the trial drug</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001876-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Results: HIV‐related adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Indicator</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control (N/98)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroid (N/99)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign="top"> <p><a href="./references#CD001876-bbs2-0002" title="ElliottAM , LuzzeH , QuigleyMA , NakiyingiJ , KyaligonzaS , NamujjuPB , et al. A randomized, double‐blind, placebo‐controlled trial of the use of prednisolone as an adjunct to treatment in HIV‐1‐associated pleural tuberculosis. Journal of Infectious Diseases2004;190(5):869‐78. ">Elliott 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kaposi’s sarcoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (6.1%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cryptococcal meningitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (5.1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (3.0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (23.5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (35.4%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (32.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (31.3%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Herpes zoster</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (19.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (22.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral or genital herpes simplex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (20.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (22.2%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (28.6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (34.3%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Abbreviations: N: number of participants</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Results: HIV‐related adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/full#CD001876-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001876-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus control (placebo or no steroids)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Residual pleural effusion on chest X‐ray <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.49, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.37, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.18, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Pleural changes at the end of treatment (pleural thickening and pleural adhesions) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>393</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.57, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Death from any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.64, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events leading to study drug discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>590</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [1.11, 6.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 HIV‐associated adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cryptococcal meningitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Oesophageal candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Oral candidiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Herpes simplex</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Herpes zoster</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Kaposi sarcoma</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus control (placebo or no steroids)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001876-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Effect of study quality on the outcome residual pleural fluid on chest X‐ray</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias excluded <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.49, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 At 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.37, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.18, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Residual pleural fluid on chest X‐ray ‐ studies at high risk of selection bias included <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.52, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 At 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.47, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 At 24 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.30, 0.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Effect of study quality on the outcome residual pleural fluid on chest X‐ray</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001876.pub3/references#CD001876-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001876.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001876-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001876-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD001876-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001876-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001876-note-0016">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001876\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001876\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001876\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001876\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001876\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001876.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001876.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001876.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001876.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001876.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725007297"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001876.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725007301"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001876.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e70b70f011bdf',t:'MTc0MDcyNTAwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 